WO2023213902A1 - Remofuscin (soraprazan) for use against lysosomal dysfunction and aging - Google Patents
Remofuscin (soraprazan) for use against lysosomal dysfunction and aging Download PDFInfo
- Publication number
- WO2023213902A1 WO2023213902A1 PCT/EP2023/061710 EP2023061710W WO2023213902A1 WO 2023213902 A1 WO2023213902 A1 WO 2023213902A1 EP 2023061710 W EP2023061710 W EP 2023061710W WO 2023213902 A1 WO2023213902 A1 WO 2023213902A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- remofuscin
- elegans
- worms
- genes
- nhr
- Prior art date
Links
- PWILYDZRJORZDR-MISYRCLQSA-N (7r,8r,9r)-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-ol Chemical compound C1([C@@H]2[C@@H](O)[C@@H](C3=C(C4=NC(C)=C(C)N4C=C3)N2)OCCOC)=CC=CC=C1 PWILYDZRJORZDR-MISYRCLQSA-N 0.000 title claims abstract description 118
- 230000002132 lysosomal effect Effects 0.000 title claims abstract description 26
- 230000032683 aging Effects 0.000 title claims abstract description 15
- 230000004064 dysfunction Effects 0.000 title claims abstract description 6
- 229950004825 soraprazan Drugs 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 230000014509 gene expression Effects 0.000 claims abstract description 45
- 239000002676 xenobiotic agent Substances 0.000 claims abstract description 31
- 230000002034 xenobiotic effect Effects 0.000 claims abstract description 30
- 150000002632 lipids Chemical class 0.000 claims abstract description 24
- 238000001784 detoxification Methods 0.000 claims abstract description 23
- 230000001965 increasing effect Effects 0.000 claims abstract description 21
- 108090001060 Lipase Proteins 0.000 claims abstract description 11
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims abstract description 11
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims abstract description 9
- 108010006519 Molecular Chaperones Proteins 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 239000013642 negative control Substances 0.000 description 26
- 239000003642 reactive oxygen metabolite Substances 0.000 description 22
- 101100182034 Caenorhabditis elegans lipl-1 gene Proteins 0.000 description 15
- 101100294114 Caenorhabditis elegans nhr-49 gene Proteins 0.000 description 15
- 101100502245 Caenorhabditis elegans lbp-8 gene Proteins 0.000 description 13
- 238000007254 oxidation reaction Methods 0.000 description 13
- 241001167795 Escherichia coli OP50 Species 0.000 description 12
- 238000011529 RT qPCR Methods 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000037356 lipid metabolism Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000010208 microarray analysis Methods 0.000 description 9
- 230000034958 pharyngeal pumping Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 235000020805 dietary restrictions Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000022814 xenobiotic metabolic process Effects 0.000 description 8
- 101100393847 Caenorhabditis elegans gst-5 gene Proteins 0.000 description 7
- 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 102000004882 Lipase Human genes 0.000 description 6
- 239000004367 Lipase Substances 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 235000019421 lipase Nutrition 0.000 description 6
- 210000003712 lysosome Anatomy 0.000 description 6
- 230000001868 lysosomic effect Effects 0.000 description 6
- 101100001271 Caenorhabditis elegans ahr-1 gene Proteins 0.000 description 5
- 101100297395 Caenorhabditis elegans pha-4 gene Proteins 0.000 description 5
- 241000244206 Nematoda Species 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 230000031018 biological processes and functions Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000001325 log-rank test Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000004879 molecular function Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 2
- 101100182036 Caenorhabditis elegans lipl-4 gene Proteins 0.000 description 2
- 101100347613 Caenorhabditis elegans unc-54 gene Proteins 0.000 description 2
- 108010023922 Enoyl-CoA hydratase Proteins 0.000 description 2
- 102000006752 Hepatocyte Nuclear Factor 4 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100028502 Transcription factor EB Human genes 0.000 description 2
- 101710162524 Transcription factor EB Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004777 loss-of-function mutation Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 101710129138 ATP synthase subunit 9, mitochondrial Proteins 0.000 description 1
- 101710168506 ATP synthase subunit C, plastid Proteins 0.000 description 1
- 101710114069 ATP synthase subunit c Proteins 0.000 description 1
- 101710197943 ATP synthase subunit c, chloroplastic Proteins 0.000 description 1
- 101710187091 ATP synthase subunit c, sodium ion specific Proteins 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 102000005869 Activating Transcription Factors Human genes 0.000 description 1
- 108010005254 Activating Transcription Factors Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 101150051438 CYP gene Proteins 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 101100438020 Caenorhabditis elegans cyp-13A2 gene Proteins 0.000 description 1
- 101100503242 Caenorhabditis elegans folt-2 gene Proteins 0.000 description 1
- 101100240530 Caenorhabditis elegans nhr-27 gene Proteins 0.000 description 1
- 101100042630 Caenorhabditis elegans sin-3 gene Proteins 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102000011426 Enoyl-CoA hydratase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- 101001004953 Homo sapiens Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000002163 Mesapamea fractilinea Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101710198640 Transcription factor jun-1 Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- GRFBKUDKDYCTIW-UHFFFAOYSA-M disodium;hydroxide;hypochlorite Chemical compound [OH-].[Na+].[Na+].Cl[O-] GRFBKUDKDYCTIW-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000048394 human LIPA Human genes 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000019758 lipid binding proteins Human genes 0.000 description 1
- 230000004918 lipophagy Effects 0.000 description 1
- 230000000512 lipotoxic effect Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- -1 nhr-234 Proteins 0.000 description 1
- 101150095464 nhr-49 gene Proteins 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Definitions
- Remofuscin for use against lysosomal dysfunction and aging
- the invention relates to new uses of remofuscin.
- Remofuscin/soraprazan is a ROS generator, specifically a superoxide generator when illuminated with light as described in EP3855181.
- ROS can degrade Lipofuscin following intravitreal injection with generators of oxygen radicals such as superoxide (Oz), peroxyl (00°), and hydroperoxyl (HOO°), in both monkeys and Abca4 - mice.
- oxygen radicals such as superoxide (Oz), peroxyl (00°), and hydroperoxyl (HOO°
- the object of the invention is to provide new uses of remofuscin, including a medical or non-medical use to extend lifespan or improve lysosomal dysfunction.
- the problem is solved by using remofuscin for pharmaceutical treatment of aging, or by using remofuscin for non-medical anti aging treatment, cosmetic treatment, or as a lifestyle drug or dietary supplement.
- remofuscin shows a significant anti-aging effect, i.e. remofuscin can be applied systemically with a positive net effect on lifespan.
- This effect surprisingly appears to require no melanin or light, and is stronger than detrimental effects that are mediated by the remofuscin ROS chemistry on aging.
- remofuscin can extend lifespan by stimulating the expression of lysosomal lipase genes and/or lysosomal lipid chaperone genes, subsequently increasing the expression levels of the genes involved in xenobiotic detoxification through nuclear hormone receptors and thereby extending lifespan.
- remofuscin can shift energy metabolism from glucose to lipid oxidation, resulting in the upregulation of beta-oxidation genes and reduces the production of ROS, thus contributing to lifespan extension.
- the lipid catabolism rate increases to supply energy, and lipid catabolism generates lipid metabolites that mediates lipotoxicity.
- remofuscin is used against lysosomal dysfunction.
- the disclosure of the invention is not limited to the compound remofuscin but also applies to tetrahydropyridoethers in general.
- Fig. 1 Effect of remofuscin on the lifespan of C. elegans (N2). Worms at the L4 stage concentrations of remofuscin. The survival rates were calculated using the Kaplan- Meier method. *p ⁇ 0.05, ***p ⁇ 0.001, log-rank test, compared with the NC.
- Fig. 2 Effect of remofuscin on aging biomarkers in C. elegans (N2). Three-day-old (day 1 of the adult stage) C. elegans fed on an E. coli OP50 lawn were transferred onto fresh mNGM plates containing E. coli OP50 and various concentrations of remofuscin, and the body lengths of 10 worms from each group were measured (A). The pumping rate in the terminal bulb was measured for 1 min every 48 h from day 4 to day 10, and the mean rate of 15 worms from each group was determined (B). *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001, Student’s t-test, compared with the NC.
- Fig. 3 Accumulation of lipofuscin in remofuscin-treated C. elegans (N2).
- B The lipofuscin fluorescence in the worms was quantified using ImageJ software. Ten worms from each group were used for the measurements. *p ⁇ 0.05, ***p ⁇ 0.001 , Student’s t-test, compared with the NC.
- Fig. 4 ROS levels in remofuscin-treated C. elegans (N2). The relative ROS levels were measured after 14 days of treatment with remofuscin. The fluorescence signal in each group (more than 80 worms for each measurement) was normalized to the protein concentration in the group. **p ⁇ 0.01, Student’s t-test, compared with the NC.
- Fig. 5 Differential gene expression between the negative control and 200 ⁇ M remofuscin-treated groups as determined by RNA microarray analysis.
- DEG analysis software (ExDEGA v.1.6.8, Ebiogen, KOR) was used to display the gene expression data as a volcano plot (A).
- the genes in the boxes are related to xenobiotic detoxification shown in Table 2 (fold change > 2.0 and p ⁇ 0.05).
- the DAVID functional annotation tool was used to analyze the gene ontology terms (B), and the biological processes associated with the DEGs revealed by microarray analysis are shown as a pie chart (C).
- Fig. 6 Expression levels of genes related to xenobiotic metabolism, lysosomes, and NHRs in remofuscin-treated C. elegans. Worms were grown on NGM plates containing 0 ⁇ M and 200 ⁇ M remofuscin for 1 and 5 days, and the gene expression levels were measured by qPCR. *p ⁇ 0.05, **p ⁇ 0.01 , ***p ⁇ 0.001, Student’s t-test, compared with the NC (0 ⁇ M remofuscin) on each day.
- Fig. 7 Expression levels of ech-9 and cyp-35A subfamily members in wild-type (N2) and nhr-234 mutant C. elegans.
- the worms were grown on NGM plates containing 0 ⁇ M and 200 ⁇ M remofuscin for 5 days, and the gene expression levels were measured by qPCR.
- Fig. 8 Predicted mechanism by which remofuscin extends the C. elegans lifespan.
- a lysosomal lipase, LI PL-1 activates lipid catabolism, similar to that in a diet restriction (DR)-like state, thereby decreasing the ROS levels and subsequently activating the xenobiotic detoxification process.
- This sequence ultimately extends the lifespan of remofuscin-treated C. elegans.
- the broken line shows the predicted route based on the previously reported pathway (Chamoli et al., 2014)
- remofuscin significantly (p ⁇ 0.05) extended the lifespan e.g. of C. elegans (N2) compared with the negative control. Aging biomarkers were improved in remofuscin-treated worms.
- genes related to lysosomes lipl-1 and lbp-8
- a nuclear hormone receptor nhr-234
- fatty acid beta-oxidation ech-9
- xenobiotic detoxification cyp-34A1 , cyp-35A1 , cyp-35A2, cyp-35A3, cyp-35A4, cyp-35A5, cyp- 35C1 , gst-28, and gst-5) were increased in remofuscin-treated worms.
- remofuscin failed to extend the lives of C.
- elegans with loss-of-function mutations (lipl- 1 , lbp-8, nhr-234, nhr-49, nhr-8, cyp-35A1 , cyp-35A2, cyp-35A3, cyp-35A5, and gst-5), showing that these genes are associated with lifespan extension in remofuscin-treated C. elegans.
- remofuscin activates the lysosome-to-nucleus pathway in C. elegans, thereby increasing the expression levels of xenobiotic detoxification genes resulted in extending their lifespan.
- remofuscin stimulates the expression of the lysosomal lipase gene lipl-1 and the lysosomal lipid chaperone gene lbp-8, subsequently increasing the expression levels of the genes involved in xenobiotic detoxification through nuclear hormone receptors and thereby extending the C. elegans lifespan.
- microarray and qPCR analyses of remofuscin-treated worms in a DR-like state revealed that genes related to lysosomes (lipl-1 and lbp-8), beta-oxidation (echo-9), and xenobiotic detoxification (cyp-34A1 , cyp-35A1, cyp-35A2, cyp-35A3, cyp-35A4, cyp-35A5, cyp-35C1, gst-28, and gst-5) are upregulated, which prevented damage caused by lipid metabolites.
- C. elegans has 8 lysosomal lipases, LI PL-1 to LI PL-8, among which LI PL-4 plays a role in the lifespan extension of C. elegans (Folick et al., 2015).
- LI PL-4 Overexpression of LI PL-4 induces the expression of the lipid chaperone protein LBP-8, and mitochondrial beta- oxidation is activated via NHR-49 and NHR-80 to promote lipid catabolism.
- ROS in mitochondria mtROS
- the LI PL-4 and LBP- 8 signaling pathways induce antioxidant targets and oxidative stress tolerance, thereby extending the C. elegans lifespan (Ramachandran et al., 2019).
- remofuscin did not increase the expression level of jun-1 in C. elegans.
- the C. elegans genes directly or indirectly involved in lipid catabolism, especially LIPL-1 respond to the DR state and control lipid metabolism (O'Rourke and Ruvkun, 2013).
- nhr-49 and nhr- 27 play roles in the longevity of C. elegans by reducing the mitochondrial electron transport chain (Khan et al., 2013). Unlike mammals, which have only 48 NHR genes, C. elegans has 284 NHR genes that play roles in various processes, including lipid and xenobiotic metabolism.
- NHR-49 a homolog of mammalian hepatocyte nuclear factor 4 (HNF4) that functions similarly to peroxisome proliferator-activated receptors (PPARs), is known to transcriptionally regulate many genes related to betaoxidation, including acyl-CoA synthetase, enoyl-CoA hydratase, and carnitine palmitoyl transferase (Pathare et al., 2012; Van Gilst et al., 2005).
- acyl-CoA synthetase acyl-CoA synthetase
- enoyl-CoA hydratase enoyl-CoA hydratase
- carnitine palmitoyl transferase PARs
- nhr-49 gene Although the expression level of the nhr-49 gene was not increased, that of ech-9 was increased in C. elegans treated with remofuscin. In addition, the nhr-49 deletion mutant failed to extend the lifespan of remofuscin-treated worms, indicating the possible role of NHR-49 in the longevity of remofuscin-treated C. elegans.
- the gene expression of nuclear receptor NHR-234 which is known to cooperate with NHR-49, was significantly upregulated in remofuscin-treated C. elegans and that the nhr-234 mutant failed to extend the lifespan of the worms.
- NHR-234 with or without NHR-49 plays a role in the longevity of remofuscin-treated worms by regulating ech-9 expression and thereafter altering the expression of genes related to xenobiotic detoxification.
- Endogenous lipofuscin the lipid-containing product resulting from the oxidation of unsaturated fatty acids composed of digested lipid-containing lysosomal residues, accumulates over time and can be a xenobiotic.
- remofuscin acts as an exogenous xenobiotic agent.
- Dependence on fatty acid oxidation for energy sources leads to the formation of lipophilic endotoxins and, in turn, activates xenobiotic detoxification genes (Lindblom and Dodd, 2006; McElwee et al., 2004).
- phase I cytochrome p450 enzymes (CYPs) chemically modify endotoxins
- phase n UDP-glucuronosyl transferases and glutathione S-transferases (GSTs) make them more soluble
- phase III modified endotoxins are emitted into the extracellular space by ATP-binding cassette transporters
- NHR-8 is required for xenobiotic resistance and may regulate the expression of cytochrome P450 genes in C. elegans (Lindblom et al., 2001), AHR-1, which is related to CYP-35A subfamily members, regulates lipid signaling (Aarnio, 2014), and PHA-4 induces the expression of xenobiotic detoxification genes (Chamoli et al., 2014).
- nhr-8 deletion mutants failed to extend the lifespan of remofuscin-treated worms, which means that genes related to xenobiotic detoxification activated by remofuscin conferred C. elegans with longevity.
- Fig. 8 a pathway that is associated with lifespan extension in remofuscin-treated C. elegans is disclosed in Fig. 8. Remofuscin increases the expression of lysosomal lipase and induces lipid catabolism (beta-oxidation), subsequently activating the xenobiotic detoxification response and extending the C. elegans lifespan.
- remofuscin-treated worms enter a DR-like state by decreasing their pharyngeal pumping rate, which is followed by a reduction in ROS levels through fatty acid beta-oxidation, thereby contributing to their lifespan extension. Lysosomal signaling from LIPL-4 to LBP-8 followed by NHR-49 and NHR-80 promotes the longevity of C. elegans (Savini et al., 2019); however, the signal herein was observed from LIPL-1 to LBP-8, followed by NHR-234 and/or NHR-49.
- Remofuscin is also known as a potent and reversible inhibitor of the H A +/K A +ATPase proton pump in cynomolgus monkeys (Julien and Schraermeyer, 2012). Although the proton pump which is inhibited by remofuscin is not present in the RPE in the eyes of human, proton pump inhibitors are known to increase the lysosomal pH, thereby activating transcription factor EB (TFEB), a master transcriptional regulator of lysosomal biogenesis, and inducing lysosomal exocytosis and autophagy (Nociari et al., 2017).
- TFEB transcription factor EB
- Remofuscin binds to lipofuscin (Julien-Schraemeyer et al., 2020) and is a superoxide generator when illuminated with light (Katairo and Takeda, 2021). Superoxide might help to degrade the polymeric lipofuscin into smaller units which then are transported out of the lysosomes by exocytosis.
- TFEB is an ortholog of HIH-30 in C. elegans, and HIH-30 is known to function as a transcription factor of lipl-1 in C. elegans in a DR-like state (O'Rourke and Ruvkun, 2013).
- LIPL-1 degrades lipids in the lysosomal lipophagy process.
- Lifespan extension derives from many factors, such as diet restriction (DR) and strengthened immunity, in a wide range of taxa ranging from yeast to primates (Hwangbo et al., 2020; Kurz and Tan, 2004).
- DR diet restriction
- Aging induces morphological and metabolic changes, such as body size alteration and lipofuscin accumulation, which thus serve as biomarkers of aging (Pincus and Slack, 2010).
- Lipid metabolism is also altered over time, and aging and longevity are thus regulated by lipid signaling (Mutlu et al., 2021). Many of the pathways regulating lifespan are linked to lipid metabolism, and lipids act as signaling molecules in longevity signaling pathways.
- DR is one of the most influential environmental interventions that extends the lifespans of a variety of species (Greer et al., 2007). Beta-oxidation genes are upregulated in a DR- like state, consequently reducing the amount of stored fat, which leads to lower reactive oxygen species (ROS) levels. ROS are known as a major cause of aging and oxidative damage (Page et al., 2010).
- C. elegans Chamoli et al., 2014.
- lysosomes play an important role in the early catabolic steps of lipid degradation (Settembre and Ballabio, 2014).
- C. elegans has eight lysosomal lipases, LIPL-1 to LIPL-8 (Seah et al., 2016); LIPL-4 has been extensively studied because it plays important roles in autophagy, fat metabolism, and lysosomal activity, which are linked to longevity in C.
- lipl-1 is the most upregulated in the fasting state, and its sequence is similar to that of human lysosomal acid lipase (BLAST scores 9e-78) (O'Rourke and Ruvkun, 2013). Remofuscin extends the lifespan of C. elegans
- Remofuscin significantly increased the MLS of wild-type C. elegans (N2) in a dose-dependent manner compared with that of the NC (0 ⁇ M remofuscin) (Table 1).
- the MLSs of C. elegans (N2) treated with 50 ⁇ M, 100 ⁇ M, and 200 ⁇ M remofuscin were increased by 9.9%, 14.6%, and 20.4%, respectively.
- the survival rates of the worms treated with remofuscin were higher than those of the untreated worms after 5 days (Fig. 1).
- age-related biomarkers body length and pharyngeal pumping rate
- a reduced pharyngeal pumping rate indicates a decrease in feeding, which can induce a DR-like state (Onken and Driscoll, 2010).
- the pharyngeal pumping rates of the remofuscin-treated groups were significantly (p ⁇ 0.05) decreased compared with that of the NC group (Fig. 2B). Regardless of whether C. elegans was treated with or without remofuscin, the pharyngeal pumping rate decreased until 6 days; however, the pumping rates of worms treated with 100 ⁇ M and 200 ⁇ M remofuscin at 8 and 10 days were nearly similar or even higher than those at 6 days. In contrast, the pharyngeal pumping rate of the NC group continuously decreased over 10 days.
- Lipofuscin accumulation is decreased in remofuscin-treated C. elegans
- Lipofuscin accumulation serves as a biomarker of aging, and remofuscin significantly decreased the lipofuscin levels in C. elegans treated with 100 ⁇ M and 200 ⁇ M remofuscin on day 14 (Fig. 3). These results show that remofuscin affects lifespan extension in C. elegans.
- GO analysis showed 10 major functional categories in the BP group, 8 categories in the CC group, and 7 categories in the MF group based on the criterion for identifying differentially expressed genes by microarray analysis (fold change > 2.0 and p ⁇ 0.05) (Fig. 5B).
- Fig. 5B those related to response to xenobiotic stimuli were highly expressed in the 200 ⁇ M remofuscin-treated worms compared with the NC worms.
- Xenobiotic detoxification is known to affect longevity in C. elegans, and based on the total significance (Fig. 5C), we focused on the genes related to xenobiotic stimulus responses.
- genes related to xenobiotic metabolism (GO: 0006805) (cyp-13A2, cyp-34A1 , cyp-35A1 , cyp-35A2, cyp-35A3, cyp-35A4, cyp-35A5, cyp-35C1 , gst-28, gst-5, ugt-65, pgp-14, and folt-2) were significantly (p ⁇ 0.05) increased (>2-fold) compared with those in the NC group (0 ⁇ M remofuscin) as determined by microarray analysis (Table 2).
- Table 2 shows that the expression levels of genes related to xenobiotic metabolism, especially cyp35A subfamily genes, were significantly increased in remofuscin-treated worms compared with NC worms (Fig. 6). Usually, the gene expression levels were higher at 5 days than at 1 day. In addition, the expression levels of lipl-1, lbp-8, and echo-9 were significantly increased in remofuscin-treated worms. Although the differences were not statistically significant, the levels of several nuclear hormone receptor (NHR) genes, transcription factors of cytochrome p450 family genes, were increased by more than 2-fold as determined by microarray analysis (Table S2). Among them, the levels of only nhr-210 and nhr-234 were significantly increased in remofuscin-treated worms compared with the NC worms as determined by qPCR analysis (Fig. 6)
- loss-of function mutants for genes related to xenobiotic detoxification were used for longevity assays.
- the loss-of function mutants available from the CGC and NBRP were selected based on the qPCR results.
- the expression levels of the transcription factor genes (nhr-49, nhr-8, ahr-1, and pha-4) related to lipid metabolism and xenobiotic stimulus responses in C. elegans were not upregulated in remofuscin- treated worms compared with the NC (Fig.
- loss-of function mutants were used to assess lifespan extension based on previous reports that they regulate the expression of genes related to lipid and xenobiotic metabolism (Chamoli et al., 2014; Folick et al., 2015; Lindblom et al., 2001 ; Menez et al., 2019; Ramachandran et al., 2019).
- Remofuscin treatment failed to extend the lifespans of worms exhibiting loss-of-function mutations of genes related to lipid metabolism (lipl-1 and lbp-8) and xenobiotic detoxification (cyp-35A1, cyp-35A2, cyp-35A3, cyp-35A5, and gst-5) (Table 3, Fig. S2).
- remofuscin failed to extend the lifespan of C. elegans harboring transcription factor (nhr-49, nhr-8, and nhr-234) mutants but not that of worms with the nhr-210 mutant.
- the ahr-1 and pha-4 deletion mutants extended the lifespans of 100 ⁇ M and 200 ⁇ M remofuscin-treated worms, respectively, their overall MLSs were decreased by remofuscin treatment compared with the wild type.
- NHR-234 cooperates with NHR-49 to induce the transcription of target genes related to lipid metabolism.
- Remofuscin-treated nematodes upregulated nhr-234 expression compared with that in the control group, and the nhr-234 mutant failed to extend the lifespan of the worms.
- NHR-234 To investigate the effect of NHR-234 on the expression of genes related to lipid metabolism and xenobiotic detoxification proposed to be downstream of NHR-234 in C.
- elegans treated with remofuscin the expression levels of ech-9, cyp- 35A1, cyp-35A2, cyp-35A3, cyp-35-A4, and cyp-35A5 in the nhr-234 deletion mutants were analyzed by qPCR.
- Escherichia coli OP50 was obtained from the Caenorhabditis Genetics Center (CGC, USA) of the University of Minnesota and used as a food for C. elegans.
- E. coli OP50 was grown in Luria-Bertani (LB) broth (Ambrothia, Daejeon, Korea) at 37 °C overnight with shaking, collected by centrifugation at 3,000x g for 10 min, washed in sterile M9 buffer, and diluted to a final concentration of 0.1 mg (wet weight) per microliter in M9 buffer (Zhao et al., 2013).
- Worms were maintained and propagated in peptone-free modified nematode growth medium (mNGM) at 25 °C according to standard techniques (Stiernagle, 2006).
- E. coli OP50 was spread on mNGM in 90-mm-diameter Petri dishes as food for the worms.
- a sodium hypochlorite-sodium hydroxide solution (Sigma Aldrich, St. Louis, MO, USA) was used to obtain viable eggs as previously described (Sulston and Hodgkin, 1988). The eggs were transferred onto fresh mNGM plates seeded with E.
- Remofuscin (kindly provided by Professor Ulrich Schraermeyer, Universitat Tubingen, Tubingen, Germany) was dissolved in dimethyl sulfoxide (DMSO, Sigma Aldrich) and administered final concentrations of 0 ⁇ M (control), 50 ⁇ M, 100 ⁇ M, and 200 ⁇ M. An equal amount of DMSO (final concentration, 0.2%) was added as the control.
- 5-Fluoro- 2'-deoxyuridine (FUdR, Sigma Aldrich) (50 ⁇ M) was added to the plates (Gruber et al., 2009), which were then seeded with E. coli OP50. The C.
- elegans mean lifespan (MLS) assay was conducted by transferring 15 young adult (L4 stage) worms onto mNGM/FUdR plates containing E. coli OP50 and treated with remofuscin at the indicated concentrations. The plates were incubated at 25 °C, and the live and dead worms were counted every 24 h. Worms were considered “dead” when they did not respond to a gentle touch with a worm picker. Nematodes that crawled off the plates and died in a non-natural manner, such as by bagging or adhering to the plate wall, were not included in the analysis (censored) (Schmeisser et al., 2013). The worms were transferred every two days to maintain a sufficient food source. All experiments were conducted three times independently at least in triplicate, and more than 100 worms were scored.
- the MLS was estimated using the following equation (Wu et al., 2006):
- j is the age (day)
- dj is the number of worms that died during the day interval (xj, x_(j+1))
- N is the total number of worms.
- SE standard error
- Worms at the L4 stage (day 1 of the adult stage) were transferred onto mNGM plates (60 mm Petri dish) containing various concentrations of remofuscin and seeded with 5 mg (wet weight) of E. coli OP50 in M9 buffer.
- the plates were incubated at 25 °C, and the body lengths of live worms were measured every 24 h until 6 days of age. In total, 10 worms per group were measured.
- C. elegans were imaged with a stereomicroscope (Olympus SZ61, Tokyo, Japan) and a ToupCam (UCMOS05100KPA, ToupTek, Hangzhou, China), and the images were analyzed by using ToupCam software. The area of the worm’s projection was estimated automatically and used as an index of body length.
- Three independent experiments were conducted for each group.
- a pharyngeal pumping rate assay was performed on mNGM plates seeded with E. coli OP50 and treated with various concentrations of remofuscin.
- Three-day-old worms (L4 stage) were transferred onto mNGM plates containing various concentrations of remofuscin and incubated at 25 °C, and the number of contractions in the terminal bulb of the pharynx was counted every 48 h for 1 min using an Olympus CKX41 inverted microscope (400*).
- Three independent experiments were conducted, and 15 worms were included in each group for each measurement.
- the autofluorescence of lipofuscin in 14-day-old adult C. elegans was measured as an aging index. Randomly selected worms from each group were placed onto 5% agar pads coated with 10 mM sodium azide (Junsei Chemical, Tokyo, Japan) in M9 buffer for anesthetization. Images of lipofuscin autofluorescence at a blue excitation wavelength (405-488 nm), which captures 4',6-diamidino-2-phenylindole (DAPI), were acquired with a laser confocal scanning microscope (Olympus 1x81 -FV1000) (Zhao et al., 2013). Fluorescence was quantified using FV10-ASW1.1 software (Olympus) to measure lipofuscin accumulation. Three independent experiments were conducted, and 10 worms were included in each group for each measurement.
- the ROS levels in C. elegans treated with 0 ⁇ M, 50 ⁇ M, 100 ⁇ M, and 200 ⁇ M remofuscin were measured for 14 days. Randomly selected worms from each group were washed twice with M9 buffer, after which the supernatant was removed, and the remaining worm pellet was suspended in 100 pL of M9 buffer. The worm pellet (100 pL) and 100 pL of 50 mM 2',7'-dichlorofluorescein diacetate (H2-DCF-DA, Sigma Aldrich) were added to the wells of a black 96-well plate.
- H2-DCF-DA 50 mM 2',7'-dichlorofluorescein diacetate
- the ROS levels were measured with a fluorescence microplate reader (SpectraMAX GEMINI EM, Molecular Devices, Sunnyvale, CA, USA) at excitation and emission wavelengths of 485 nm and 520 nm, respectively, at 90 min after activation.
- the fluorescence signal in each group which included more than 80 worms for each measurement, was normalized to the protein concentration in each group. Three independent experiments were conducted.
- TRIzol Invitrogen, Carlsbad, CA, USA
- the synthesis of target cRNA probes and hybridization were performed using an Aligent Lowlnput QuickAmp labeling kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer’s instructions.
- Amplified and labeled cRNA was purified on a cRNA Cleanup Module (Agilent Technologies), and labeled cRNA targets were quantified using an ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA). After checking the labeling efficiency, the cRNA was fragmented by adding 10X blocking agent and 25X fragmentation buffer and incubating at 60 °C for 30 min. The fragmented cRNA was resuspended in 2X hybridization buffer and directly pipetted onto assembled C. elegans oligo microarrays (Agilent, 44K). The arrays were hybridized at 65 °C for 17 h using a hybridization oven (Agilent Technologies).
- the hybridized microarrays were washed according to the manufacturer’s protocol (Agilent Technologies). The hybridized images were scanned using an Agilent DNA microarray scanner and quantified with Feature Extraction 10.7 software (Agilent Technologies). Raw intensity data were globally normalized (Cheadle et al., 2003). All data normalization and selection of differentially expressed genes (fold change) were performed using GeneSpring GX 7.3.1 (Agilent Technologies). The criterion for the identification of genes with significantly altered expression was a p value ⁇ 0.05 compared with the negative control. The RNA sequencing data were deposited in the NCBI Gene Expression Omnibus (GEO) database (accession code: GSE144059).
- GEO Gene Expression Omnibus
- TAF-4 is required for the life extension of isp-1, clk-1 and tpk-1 Mit mutants. Aging (Albany NY) 5, 741-758.
- the transcription factor NHR-8 A new target to increase ivermectin efficacy in nematodes. PLoS Pathog. 15, e1007598.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Birds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to remofuscin for use against aging, lysomal dysfunction, for use in stimulating the expression of lysosomal lipase genes and/or lysosomal lipid chaperone genes, and for use in increasing the expression levels of the genes involved in xenobiotic detoxification through nuclear hormone receptors.
Description
Remofuscin (soraprazan) for use against lysosomal dysfunction and aging
FIELD OF THE INVENTION
The invention relates to new uses of remofuscin.
BACKGROUND OF THE INVENTION
Remofuscin/soraprazan is a ROS generator, specifically a superoxide generator when illuminated with light as described in EP3855181. ROS can degrade Lipofuscin following intravitreal injection with generators of oxygen radicals such as superoxide (Oz), peroxyl (00°), and hydroperoxyl (HOO°), in both monkeys and Abca4 - mice.
In the C. Elegans model ROS has been shown to induce enhanced autophagy and decreased lifespan in sin-3 deletion mutants (Meenakshi et al., Autophagy. 2018; 14(7): 1239-1255).
Further, in albino mice lipofuscin degradation has been minimal, suggesting that melanin is required for degradation. Melanin is not present in many organs affected by aging.
The object of the invention is to provide new uses of remofuscin, including a medical or non-medical use to extend lifespan or improve lysosomal dysfunction.
DESCRIPTION OF THE INVENTION
The above-mentioned problem is solved by the invention according to the appended claims. In particular, the problem is solved by using remofuscin for pharmaceutical treatment of aging, or by using remofuscin for non-medical anti aging treatment, cosmetic treatment, or as a lifestyle drug or dietary supplement.
Surprisingly, the inventors have found that the administration of remofuscin can extend lifespan and equally surprisingly reduces ROS.
Specifically, the inventors have found that systemic administration of remofuscin shows a significant anti-aging effect, i.e. remofuscin can be applied systemically with a positive net effect on lifespan. This effect surprisingly appears to require no melanin or light, and is stronger than detrimental effects that are mediated by the remofuscin ROS chemistry on aging.
According to a further aspect of the invention remofuscin can extend lifespan by stimulating the expression of lysosomal lipase genes and/or lysosomal lipid chaperone genes, subsequently increasing the expression levels of the genes involved in xenobiotic detoxification through nuclear hormone receptors and thereby extending lifespan.
According to another aspect of the invention remofuscin can shift energy metabolism from glucose to lipid oxidation, resulting in the upregulation of beta-oxidation genes and reduces the production of ROS, thus contributing to lifespan extension.
In the dietary restriction (DR) state, the lipid catabolism rate increases to supply energy, and lipid catabolism generates lipid metabolites that mediates lipotoxicity.
According to another aspect of the invention remofuscin is used against lysosomal dysfunction.
The disclosure of the invention is not limited to the compound remofuscin but also applies to tetrahydropyridoethers in general.
BRIEF DESCRIPTION OF THE FIGURES
Fig. 1. Effect of remofuscin on the lifespan of C. elegans (N2). Worms at the L4 stage
concentrations of remofuscin. The survival rates were calculated using the Kaplan- Meier method. *p < 0.05, ***p < 0.001, log-rank test, compared with the NC.
Fig. 2. Effect of remofuscin on aging biomarkers in C. elegans (N2). Three-day-old (day 1 of the adult stage) C. elegans fed on an E. coli OP50 lawn were transferred onto fresh mNGM plates containing E. coli OP50 and various concentrations of remofuscin, and the body lengths of 10 worms from each group were measured (A). The pumping rate in the terminal bulb was measured for 1 min every 48 h from day 4 to day 10, and the mean rate of 15 worms from each group was determined (B). *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t-test, compared with the NC.
Fig. 3. Accumulation of lipofuscin in remofuscin-treated C. elegans (N2). (A) Images of lipofuscin fluorescence in worms treated with various concentrations of remofuscin on day 14 (scale bar = 100 pm). (B) The lipofuscin fluorescence in the worms was quantified using ImageJ software. Ten worms from each group were used for the measurements. *p < 0.05, ***p < 0.001 , Student’s t-test, compared with the NC.
Fig. 4. ROS levels in remofuscin-treated C. elegans (N2). The relative ROS levels were measured after 14 days of treatment with remofuscin. The fluorescence signal in each group (more than 80 worms for each measurement) was normalized to the protein concentration in the group. **p < 0.01, Student’s t-test, compared with the NC.
Fig. 5. Differential gene expression between the negative control and 200 μM remofuscin-treated groups as determined by RNA microarray analysis. DEG analysis software (ExDEGA v.1.6.8, Ebiogen, KOR) was used to display the gene expression data as a volcano plot (A). The genes in the boxes are related to xenobiotic detoxification shown in Table 2 (fold change > 2.0 and p < 0.05). The DAVID functional annotation tool was used to analyze the gene ontology terms (B), and the biological processes associated with the DEGs revealed by microarray analysis are shown as a pie chart (C).
Fig. 6. Expression levels of genes related to xenobiotic metabolism, lysosomes, and NHRs in remofuscin-treated C. elegans. Worms were grown on NGM plates containing 0 μM and 200 μM remofuscin for 1 and 5 days, and the gene expression levels were measured by qPCR. *p < 0.05, **p < 0.01 , ***p < 0.001, Student’s t-test, compared with the NC (0 μM remofuscin) on each day.
Fig. 7. Expression levels of ech-9 and cyp-35A subfamily members in wild-type (N2) and nhr-234 mutant C. elegans. The worms were grown on NGM plates containing 0 μM and 200 μM remofuscin for 5 days, and the gene expression levels were measured by qPCR. *p < 0.05, **p < 0.01 , ***p < 0.001, Student’s t-test, compared with the wild-
type (N2) NC and ###p < 0.001 , Student’s t-test, compared with the 200 μM remofuscin-treated wild-type (N2) worms.
Fig. 8. Predicted mechanism by which remofuscin extends the C. elegans lifespan. A lysosomal lipase, LI PL-1 , activates lipid catabolism, similar to that in a diet restriction (DR)-like state, thereby decreasing the ROS levels and subsequently activating the xenobiotic detoxification process. This sequence ultimately extends the lifespan of remofuscin-treated C. elegans. The broken line shows the predicted route based on the previously reported pathway (Chamoli et al., 2014)
EXAMPLES
As shown below remofuscin significantly (p < 0.05) extended the lifespan e.g. of C. elegans (N2) compared with the negative control. Aging biomarkers were improved in remofuscin-treated worms.
Surprisingly, the expression levels of genes related to lysosomes (lipl-1 and lbp-8), a nuclear hormone receptor (nhr-234), fatty acid beta-oxidation (ech-9), and xenobiotic detoxification (cyp-34A1 , cyp-35A1 , cyp-35A2, cyp-35A3, cyp-35A4, cyp-35A5, cyp- 35C1 , gst-28, and gst-5) were increased in remofuscin-treated worms. Moreover, remofuscin failed to extend the lives of C. elegans with loss-of-function mutations (lipl- 1 , lbp-8, nhr-234, nhr-49, nhr-8, cyp-35A1 , cyp-35A2, cyp-35A3, cyp-35A5, and gst-5), showing that these genes are associated with lifespan extension in remofuscin-treated C. elegans. In conclusion, remofuscin activates the lysosome-to-nucleus pathway in C. elegans, thereby increasing the expression levels of xenobiotic detoxification genes resulted in extending their lifespan.
As shown in Fig. 2, remofuscin stimulates the expression of the lysosomal lipase gene lipl-1 and the lysosomal lipid chaperone gene lbp-8, subsequently increasing the expression levels of the genes involved in xenobiotic detoxification through nuclear hormone receptors and thereby extending the C. elegans lifespan.
The microarray and qPCR analyses of remofuscin-treated worms in a DR-like state revealed that genes related to lysosomes (lipl-1 and lbp-8), beta-oxidation (echo-9), and xenobiotic detoxification (cyp-34A1 , cyp-35A1, cyp-35A2, cyp-35A3, cyp-35A4, cyp-35A5, cyp-35C1, gst-28, and gst-5) are upregulated, which prevented damage caused by lipid metabolites.
C. elegans has 8 lysosomal lipases, LI PL-1 to LI PL-8, among which LI PL-4 plays a role in the lifespan extension of C. elegans (Folick et al., 2015). Overexpression of LI PL-4 induces the expression of the lipid chaperone protein LBP-8, and mitochondrial beta-
oxidation is activated via NHR-49 and NHR-80 to promote lipid catabolism. ROS in mitochondria (mtROS) activate the transcription factor JUN-1 , and the LI PL-4 and LBP- 8 signaling pathways induce antioxidant targets and oxidative stress tolerance, thereby extending the C. elegans lifespan (Ramachandran et al., 2019). However, remofuscin did not increase the expression level of jun-1 in C. elegans. The C. elegans genes directly or indirectly involved in lipid catabolism, especially LIPL-1 , respond to the DR state and control lipid metabolism (O'Rourke and Ruvkun, 2013).
Below it is shown that the expression levels of genes related to a lysosomal lipase (lipl- 1), a lipid binding protein (lbp-8), and beta-oxidation (ech-9) are increased in remofuscin-treated worms. In addition to jun-1 , the transcription factors nhr-49 and nhr- 27 play roles in the longevity of C. elegans by reducing the mitochondrial electron transport chain (Khan et al., 2013). Unlike mammals, which have only 48 NHR genes, C. elegans has 284 NHR genes that play roles in various processes, including lipid and xenobiotic metabolism. In particular, NHR-49, a homolog of mammalian hepatocyte nuclear factor 4 (HNF4) that functions similarly to peroxisome proliferator-activated receptors (PPARs), is known to transcriptionally regulate many genes related to betaoxidation, including acyl-CoA synthetase, enoyl-CoA hydratase, and carnitine palmitoyl transferase (Pathare et al., 2012; Van Gilst et al., 2005). However, the effect of NHR- 49 on ech-9 (enoyl-CoA hydratase gene) remains debatable (Chamoli et al., 2014; Van Gilst et al., 2005).
Although the expression level of the nhr-49 gene was not increased, that of ech-9 was increased in C. elegans treated with remofuscin. In addition, the nhr-49 deletion mutant failed to extend the lifespan of remofuscin-treated worms, indicating the possible role of NHR-49 in the longevity of remofuscin-treated C. elegans. The gene expression of nuclear receptor NHR-234, which is known to cooperate with NHR-49, was significantly upregulated in remofuscin-treated C. elegans and that the nhr-234 mutant failed to extend the lifespan of the worms. Unlike the wild-type (N2) worms, those with nhr-234 deletion mutants (VC1806) did not exhibit increased expression levels of the genes related to lipid metabolism (ech-9) and xenobiotic stimulus responses (cyp-35A2, cyp- 35A3, and cyp-35A4), which may be regulated by NHR-239. Thus, NHR-234 with or without NHR-49 plays a role in the longevity of remofuscin-treated worms by regulating ech-9 expression and thereafter altering the expression of genes related to xenobiotic detoxification.
Endogenous lipofuscin, the lipid-containing product resulting from the oxidation of unsaturated fatty acids composed of digested lipid-containing lysosomal residues, accumulates over time and can be a xenobiotic.
According to the invention, remofuscin acts as an exogenous xenobiotic agent. Dependence on fatty acid oxidation for energy sources leads to the formation of lipophilic endotoxins and, in turn, activates xenobiotic detoxification genes (Lindblom and Dodd, 2006; McElwee et al., 2004).
Xenobiotic detoxification occurs in three phases: phase I (cytochrome p450 enzymes (CYPs) chemically modify endotoxins), phase n (UDP-glucuronosyl transferases and glutathione S-transferases (GSTs) make them more soluble), and finally, phase III (modified endotoxins are emitted into the extracellular space by ATP-binding cassette transporters) (Lindblom and Dodd, 2006; Sharom, 2011). The expression levels of cyp (cytochrome p450 enzymes) and gst (glutathione S-transferases) genes were increased in remofuscin-treated C. elegans. GST functions as an antioxidant in detoxification reactions and inhibits ROS generation. In addition, GST stops or slows lipofuscin formation and cleaves the existing lipofuscin (Vekshin and Frolova, 2018). The transcription factors NHR-8, AHR-1, and PHA-4 regulate the expression of genes related to xenobiotic metabolism. NHR-8 is required for xenobiotic resistance and may regulate the expression of cytochrome P450 genes in C. elegans (Lindblom et al., 2001), AHR-1, which is related to CYP-35A subfamily members, regulates lipid signaling (Aarnio, 2014), and PHA-4 induces the expression of xenobiotic detoxification genes (Chamoli et al., 2014). nhr-8 deletion mutants failed to extend the lifespan of remofuscin-treated worms, which means that genes related to xenobiotic detoxification activated by remofuscin conferred C. elegans with longevity.
Based on the results a pathway that is associated with lifespan extension in remofuscin-treated C. elegans is disclosed in Fig. 8. Remofuscin increases the expression of lysosomal lipase and induces lipid catabolism (beta-oxidation), subsequently activating the xenobiotic detoxification response and extending the C. elegans lifespan.
In addition, remofuscin-treated worms enter a DR-like state by decreasing their pharyngeal pumping rate, which is followed by a reduction in ROS levels through fatty acid beta-oxidation, thereby contributing to their lifespan extension. Lysosomal signaling from LIPL-4 to LBP-8 followed by NHR-49 and NHR-80 promotes the longevity of C. elegans (Savini et al., 2019); however, the signal herein was observed from LIPL-1 to LBP-8, followed by NHR-234 and/or NHR-49.
Remofuscin is also known as a potent and reversible inhibitor of the HA+/KA+ATPase proton pump in cynomolgus monkeys (Julien and Schraermeyer, 2012). Although the proton pump which is inhibited by remofuscin is not present in the RPE in the eyes of human, proton pump inhibitors are known to increase the lysosomal pH, thereby activating transcription factor EB (TFEB), a master transcriptional regulator of
lysosomal biogenesis, and inducing lysosomal exocytosis and autophagy (Nociari et al., 2017). Remofuscin binds to lipofuscin (Julien-Schraemeyer et al., 2020) and is a superoxide generator when illuminated with light (Katairo and Takeda, 2021). Superoxide might help to degrade the polymeric lipofuscin into smaller units which then are transported out of the lysosomes by exocytosis. TFEB is an ortholog of HIH-30 in C. elegans, and HIH-30 is known to function as a transcription factor of lipl-1 in C. elegans in a DR-like state (O'Rourke and Ruvkun, 2013).
Additionally, LIPL-1 degrades lipids in the lysosomal lipophagy process.
Lifespan extension derives from many factors, such as diet restriction (DR) and strengthened immunity, in a wide range of taxa ranging from yeast to primates (Hwangbo et al., 2020; Kurz and Tan, 2004). DR reduces the body size of Caenorhabditis elegans, which is associated with an extended lifespan (Bishop and Guarente, 2007). Aging induces morphological and metabolic changes, such as body size alteration and lipofuscin accumulation, which thus serve as biomarkers of aging (Pincus and Slack, 2010). Lipid metabolism is also altered over time, and aging and longevity are thus regulated by lipid signaling (Mutlu et al., 2021). Many of the pathways regulating lifespan are linked to lipid metabolism, and lipids act as signaling molecules in longevity signaling pathways.
In C. elegans, a reduced pharyngeal pumping rate is associated with a lower food intake, which results in a DR-like state despite an abundant supply of food. DR is one of the most influential environmental interventions that extends the lifespans of a variety of species (Greer et al., 2007). Beta-oxidation genes are upregulated in a DR- like state, consequently reducing the amount of stored fat, which leads to lower reactive oxygen species (ROS) levels. ROS are known as a major cause of aging and oxidative damage (Page et al., 2010).
Increased fatty acid beta-oxidation induces the expression of xenobiotic detoxification genes to clear lipophilic endotoxins produced during lipid catabolism, and the resulting metabolic shift increases the longevity of C. elegans (Chamoli et al., 2014). In the DR state, lysosomes play an important role in the early catabolic steps of lipid degradation (Settembre and Ballabio, 2014). C. elegans has eight lysosomal lipases, LIPL-1 to LIPL-8 (Seah et al., 2016); LIPL-4 has been extensively studied because it plays important roles in autophagy, fat metabolism, and lysosomal activity, which are linked to longevity in C. elegans (Lapierre et al., 2011; Wang et al., 2008; Watts and Ristow, 2017). Among the lysosomal lipase genes, lipl-1 is the most upregulated in the fasting state, and its sequence is similar to that of human lysosomal acid lipase (BLAST scores 9e-78) (O'Rourke and Ruvkun, 2013).
Remofuscin extends the lifespan of C. elegans
Remofuscin significantly (p < 0.05) increased the MLS of wild-type C. elegans (N2) in a dose-dependent manner compared with that of the NC (0 μM remofuscin) (Table 1). Compared with those of the NCs, the MLSs of C. elegans (N2) treated with 50 μM, 100 μM, and 200 μM remofuscin were increased by 9.9%, 14.6%, and 20.4%, respectively. The survival rates of the worms treated with remofuscin were higher than those of the untreated worms after 5 days (Fig. 1).
Table 1
The mean lifespans (MLSs) of C. elegans (N2) treated with various concentrations of remofuscin. *p < 0.05, ***p < 0.001, log-rank test, compared with the NC (0 μM remofuscin)
Effects of remofuscin on age-related biomarkers in C. elegans
To investigate the effect of remofuscin on lifespan extension in C. elegans, age-related biomarkers (body length and pharyngeal pumping rate) were measured. The body lengths of the live worms were measured every 24 h until 6 days of age. While the body length increased with age in all the groups, those of the remofuscin-treated groups were significantly shorter than those of the NC group (Fig. 2A).
A reduced pharyngeal pumping rate indicates a decrease in feeding, which can induce a DR-like state (Onken and Driscoll, 2010). The pharyngeal pumping rates of the remofuscin-treated groups were significantly (p < 0.05) decreased compared with that of the NC group (Fig. 2B). Regardless of whether C. elegans was treated with or
without remofuscin, the pharyngeal pumping rate decreased until 6 days; however, the pumping rates of worms treated with 100 μM and 200 μM remofuscin at 8 and 10 days were nearly similar or even higher than those at 6 days. In contrast, the pharyngeal pumping rate of the NC group continuously decreased over 10 days.
Lipofuscin accumulation is decreased in remofuscin-treated C. elegans
Lipofuscin accumulation serves as a biomarker of aging, and remofuscin significantly decreased the lipofuscin levels in C. elegans treated with 100 μM and 200 μM remofuscin on day 14 (Fig. 3). These results show that remofuscin affects lifespan extension in C. elegans.
Effects of remofuscin-induced ROS reductions in C. elegans
To investigate the inhibitory effect of remofuscin on ROS generation in C. elegans, the total ROS levels in worms treated with remofuscin were measured. The ROS levels in C. elegans grown on plates containing 100 μM and 200 μM remofuscin for 14 days were significantly (p < 0.05) decreased compared with those in the NC group (Fig. 4).
Microarray analysis of remofuscin-treated C. elegans
To investigate the mechanism by which remofuscin promotes longevity, microarray analysis of wild-type (N2) worms treated with 0 μM (NC) and 200 μM remofuscin for 14 days was performed. A total of 31 ,383 genes were identified, among which 340 and 103 genes were significantly (p < 0.05) upregulated (> 2-fold) and downregulated (< 0.5-fold), respectively, between the NC and 200 μM remofuscin-treated worms (Fig. 5A). Based on the terms represented in the GO database, the differentially expressed genes (DEGs) were divided into three categories: biological process (BP), cellular component (CC), and molecular function (MF). GO analysis showed 10 major functional categories in the BP group, 8 categories in the CC group, and 7 categories in the MF group based on the criterion for identifying differentially expressed genes by microarray analysis (fold change > 2.0 and p < 0.05) (Fig. 5B). Among these genes, those related to response to xenobiotic stimuli were highly expressed in the 200 μM remofuscin-treated worms compared with the NC worms. Xenobiotic detoxification is known to affect longevity in C. elegans, and based on the total significance (Fig. 5C), we focused on the genes related to xenobiotic stimulus responses. The genes related to xenobiotic metabolism (GO: 0006805) (cyp-13A2, cyp-34A1 , cyp-35A1 , cyp-35A2, cyp-35A3, cyp-35A4, cyp-35A5, cyp-35C1 , gst-28, gst-5, ugt-65, pgp-14, and folt-2) were significantly (p < 0.05) increased (>2-fold) compared with those in the NC group (0 μM remofuscin) as determined by microarray analysis (Table 2).
Table 2
Microarray analysis revealed that xenobiotic metabolism-related genes were upregulated in C. elegans (N2) treated with 200 μM remofuscin. Fold changes were calculated between the control and remofuscin (200 μM)-treated C. elegans.
Effects of remofuscin on the expression levels of genes related to lysosomes and xenobiotic metabolism.
Based on the microarray results, the expression levels of genes related to lysosomal lipases (lipl-1 ), long-chain fatty acid transporters (lbp-8), fatty acid beta-oxidation (echo- 9), and xenobiotic detoxification (cyp-35A subfamily, gst-5, and gst-28) in C. elegans (N2) treated with 0 and 200 μM remofuscin for 1 day and 5 days were measured by qPCR. Table 2 shows that the expression levels of genes related to xenobiotic metabolism, especially cyp35A subfamily genes, were significantly increased in remofuscin-treated worms compared with NC worms (Fig. 6). Mostly, the gene expression levels were higher at 5 days than at 1 day. In addition, the expression levels of lipl-1, lbp-8, and echo-9 were significantly increased in remofuscin-treated worms. Although the differences were not statistically significant, the levels of several nuclear hormone receptor (NHR) genes, transcription factors of cytochrome p450 family genes, were increased by more than 2-fold as determined by microarray analysis (Table S2). Among them, the levels of only nhr-210 and nhr-234 were significantly increased in remofuscin-treated worms compared with the NC worms as determined by qPCR analysis (Fig. 6)
Longevity assay of loss-of-function mutants
To elucidate the mechanism by which remofuscin extends the C. elegans lifespan, loss-of function mutants for genes related to xenobiotic detoxification were used for longevity assays. The loss-of function mutants available from the CGC and NBRP were selected based on the qPCR results. In addition, although the expression levels of the transcription factor genes (nhr-49, nhr-8, ahr-1, and pha-4) related to lipid metabolism and xenobiotic stimulus responses in C. elegans were not upregulated in remofuscin- treated worms compared with the NC (Fig. S1), loss-of function mutants were used to assess lifespan extension based on previous reports that they regulate the expression of genes related to lipid and xenobiotic metabolism (Chamoli et al., 2014; Folick et al., 2015; Lindblom et al., 2001 ; Menez et al., 2019; Ramachandran et al., 2019). Remofuscin treatment failed to extend the lifespans of worms exhibiting loss-of-function mutations of genes related to lipid metabolism (lipl-1 and lbp-8) and xenobiotic detoxification (cyp-35A1, cyp-35A2, cyp-35A3, cyp-35A5, and gst-5) (Table 3, Fig. S2). Interestingly, remofuscin failed to extend the lifespan of C. elegans harboring transcription factor (nhr-49, nhr-8, and nhr-234) mutants but not that of worms with the nhr-210 mutant. Although the ahr-1 and pha-4 deletion mutants extended the lifespans of 100 μM and 200 μM remofuscin-treated worms, respectively, their overall MLSs were decreased by remofuscin treatment compared with the wild type.
Table 3
The mean lifespans of C. elegans with loss-of-function mutants, n, The number of total worms; *p < 0.05, **p < 0.01 , ***p < 0.001 , log-rank test, compared with the NC.
Role of N HR-234 in the longevity mechanism of remofuscin
NHR-234 cooperates with NHR-49 to induce the transcription of target genes related to lipid metabolism. Remofuscin-treated nematodes upregulated nhr-234 expression compared with that in the control group, and the nhr-234 mutant failed to extend the lifespan of the worms. To investigate the effect of NHR-234 on the expression of genes related to lipid metabolism and xenobiotic detoxification proposed to be downstream of NHR-234 in C. elegans treated with remofuscin, the expression levels of ech-9, cyp- 35A1, cyp-35A2, cyp-35A3, cyp-35-A4, and cyp-35A5 in the nhr-234 deletion mutants were analyzed by qPCR. The expression levels of ech-9, cyp-35A2, cyp-35A3, and cyp-35-A4, but not cyp-35A1 and cyp-35A5, were not increased in the nhr-234 deletion mutants treated with remofuscin (200 μM) compared with the wild-type (N2) worms, indicating that NHR-234 might regulate their expression (Fig. 7).
Materials and methods
Bacterial strains and culture conditions
Escherichia coli OP50 was obtained from the Caenorhabditis Genetics Center (CGC, USA) of the University of Minnesota and used as a food for C. elegans. E. coli OP50 was grown in Luria-Bertani (LB) broth (Ambrothia, Daejeon, Korea) at 37 °C overnight with shaking, collected by centrifugation at 3,000x g for 10 min, washed in sterile M9 buffer, and diluted to a final concentration of 0.1 mg (wet weight) per microliter in M9 buffer (Zhao et al., 2013).
Nematode strains and growth conditions
C. elegans Bristol strain N2, provided by the CGC, was used as the wild-type strain. The mutant strains VC1806 nhr-234 (gk865), VC4077 lbp-8 (gk5151[loxP + myo- 2p::GFP::unc-54 3' UTR + rps-27p::neoR::unc-54 3' UTR + loxP]), VC875 cyp-35A1 (ok1414), RB2046 cyp-35A3 (ok2709), and RB2063 gst-5 (ok2726) were provided by the CGC, and FX1954 lipl-1 (tm1954), FX1290 nhr-210 (tm1290), FX30306 nhr-49 (tm7967), FX19275 nhr-8 (tm1800), FX01722 ahr-1 (tm1722), FX4598 pha-4 (tm4598), FX21842 cyp-35A2 (tm11844), and FX22344 cyp-35A5 (tm 12345) were provided by the National Bioresource Project (NBRP) for nematodes at Tokyo Women's Medical University (Tokyo, Japan). Worms were maintained and propagated in peptone-free modified nematode growth medium (mNGM) at 25 °C according to standard techniques (Stiernagle, 2006). E. coli OP50 was spread on mNGM in 90-mm-diameter Petri dishes as food for the worms. A sodium hypochlorite-sodium hydroxide solution (Sigma Aldrich, St. Louis, MO, USA) was used to obtain viable eggs as previously described (Sulston and Hodgkin, 1988). The eggs were transferred onto fresh mNGM plates seeded with E. coli OP50 and incubated at 25 °C until the L4 stage (3-day-old worms), and all experiments used the L4 stage (3-day-old worms) as day 1 of the adult stage to control the reproductive system in C. elegans (Komura et al., 2013).
Assay of the C. elegans mean lifespan
Remofuscin (kindly provided by Professor Ulrich Schraermeyer, Universitat Tubingen, Tubingen, Germany) was dissolved in dimethyl sulfoxide (DMSO, Sigma Aldrich) and administered final concentrations of 0 μM (control), 50 μM, 100 μM, and 200 μM. An equal amount of DMSO (final concentration, 0.2%) was added as the control. 5-Fluoro- 2'-deoxyuridine (FUdR, Sigma Aldrich) (50 μM) was added to the plates (Gruber et al., 2009), which were then seeded with E. coli OP50. The C. elegans mean lifespan (MLS) assay was conducted by transferring 15 young adult (L4 stage) worms onto mNGM/FUdR plates containing E. coli OP50 and treated with remofuscin at the indicated concentrations. The plates were incubated at 25 °C, and the live and dead worms were counted every 24 h. Worms were considered “dead” when they did not respond to a gentle touch with a worm picker. Nematodes that crawled off the plates and died in a non-natural manner, such as by bagging or adhering to the plate wall, were not included in the analysis (censored) (Schmeisser et al., 2013). The worms were transferred every two days to maintain a sufficient food source. All experiments were conducted three times independently at least in triplicate, and more than 100 worms were scored.
In the equation, j is the age (day), djis the number of worms that died during the day interval (xj, x_(j+1)), and N is the total number of worms. The standard error (SE) of the estimated MLS was calculated using the following formula.
Measurement of body length
Worms at the L4 stage (day 1 of the adult stage) were transferred onto mNGM plates (60 mm Petri dish) containing various concentrations of remofuscin and seeded with 5 mg (wet weight) of E. coli OP50 in M9 buffer. The plates were incubated at 25 °C, and the body lengths of live worms were measured every 24 h until 6 days of age. In total, 10 worms per group were measured. C. elegans were imaged with a stereomicroscope (Olympus SZ61, Tokyo, Japan) and a ToupCam (UCMOS05100KPA, ToupTek, Hangzhou, China), and the images were analyzed by using ToupCam software. The
area of the worm’s projection was estimated automatically and used as an index of body length. Three independent experiments were conducted for each group.
Measurement of the pharyngeal pumping rate
A pharyngeal pumping rate assay was performed on mNGM plates seeded with E. coli OP50 and treated with various concentrations of remofuscin. Three-day-old worms (L4 stage) were transferred onto mNGM plates containing various concentrations of remofuscin and incubated at 25 °C, and the number of contractions in the terminal bulb of the pharynx was counted every 48 h for 1 min using an Olympus CKX41 inverted microscope (400*). Three independent experiments were conducted, and 15 worms were included in each group for each measurement.
Measurement of lipofuscin accumulation
The autofluorescence of lipofuscin in 14-day-old adult C. elegans was measured as an aging index. Randomly selected worms from each group were placed onto 5% agar pads coated with 10 mM sodium azide (Junsei Chemical, Tokyo, Japan) in M9 buffer for anesthetization. Images of lipofuscin autofluorescence at a blue excitation wavelength (405-488 nm), which captures 4',6-diamidino-2-phenylindole (DAPI), were acquired with a laser confocal scanning microscope (Olympus 1x81 -FV1000) (Zhao et al., 2013). Fluorescence was quantified using FV10-ASW1.1 software (Olympus) to measure lipofuscin accumulation. Three independent experiments were conducted, and 10 worms were included in each group for each measurement.
Measurement of ROS
The ROS levels in C. elegans treated with 0 μM, 50 μM, 100 μM, and 200 μM remofuscin were measured for 14 days. Randomly selected worms from each group were washed twice with M9 buffer, after which the supernatant was removed, and the remaining worm pellet was suspended in 100 pL of M9 buffer. The worm pellet (100 pL) and 100 pL of 50 mM 2',7'-dichlorofluorescein diacetate (H2-DCF-DA, Sigma Aldrich) were added to the wells of a black 96-well plate. The ROS levels were measured with a fluorescence microplate reader (SpectraMAX GEMINI EM, Molecular Devices, Sunnyvale, CA, USA) at excitation and emission wavelengths of 485 nm and 520 nm, respectively, at 90 min after activation. The fluorescence signal in each group, which included more than 80 worms for each measurement, was normalized to the protein concentration in each group. Three independent experiments were conducted.
Microarray analysis
Worms fed E. coli OP50 for 14 days on NGM plates containing 0 μM and 200 μM remofuscin were collected and washed twice with M9 buffer, after which total RNA was isolated from whole worms using TRIzol (Invitrogen, Carlsbad, CA, USA) according to a previously described method (Greer et al., 2007). For each RNA, the synthesis of
target cRNA probes and hybridization were performed using an Aligent Lowlnput QuickAmp labeling kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer’s instructions. Amplified and labeled cRNA was purified on a cRNA Cleanup Module (Agilent Technologies), and labeled cRNA targets were quantified using an ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA). After checking the labeling efficiency, the cRNA was fragmented by adding 10X blocking agent and 25X fragmentation buffer and incubating at 60 °C for 30 min. The fragmented cRNA was resuspended in 2X hybridization buffer and directly pipetted onto assembled C. elegans oligo microarrays (Agilent, 44K). The arrays were hybridized at 65 °C for 17 h using a hybridization oven (Agilent Technologies). The hybridized microarrays were washed according to the manufacturer’s protocol (Agilent Technologies). The hybridized images were scanned using an Agilent DNA microarray scanner and quantified with Feature Extraction 10.7 software (Agilent Technologies). Raw intensity data were globally normalized (Cheadle et al., 2003). All data normalization and selection of differentially expressed genes (fold change) were performed using GeneSpring GX 7.3.1 (Agilent Technologies). The criterion for the identification of genes with significantly altered expression was a p value < 0.05 compared with the negative control. The RNA sequencing data were deposited in the NCBI Gene Expression Omnibus (GEO) database (accession code: GSE144059). For the pie chart and volcano plot, Excel-based Differentially Expressed Gene Analysis (ExDEGA, eBiogen, Seoul, Korea) software was used to analyze the microarray data according to classified Gene Ontology (GO) terms. Genes with a p-value < 0.05 and a fold change of 2.0 compared with the negative control were defined as significantly changed genes.
Quantitative real-time polymerase chain reaction (qPCR)
C. elegans fed E. coli OP50 for 1 and 5 days on NGM plates containing 0 μM and 200 μM remofuscin were collected and washed twice with M9 buffer. Total mRNA was isolated from whole worms using TRIzol (Invitrogen) as previously described (Greer et al., 2007). The RNA was converted into cDNA using a RevertAid First Strand cDNA Synthesis Kit according to the manufacturer’s instructions (Thermo Scientific, Wilmington, DE, USA) and then amplified by qPCR using SYBR Green (KAPA Biosystems, Wilmington, MA, USA) and a QuantStudio 6 Flex Real Time PCR machine (Applied Biosystems, Foster City, CA, USA). For qPCR, an initial step at 95 °C followed by 40 cycles of 95 °C for 15 s, 60 °C for 15 s, and 72 °C for 30 s were performed, and melting curve analysis was performed. The experiments were independently conducted at least three times, and relative expression levels were calculated using the 2-AACT method (Livak and Schmittgen, 2001). The internal control gene act-1 was used to normalize the gene expression data. The sequences of the primers used are listed in Table S1.
Statistical analysis
In the lifespan assay, the Kaplan-Meier method and the log-rank test were used to calculate the MLS and p-values, respectively (Zhao et al., 2013). In the other experiments, the significance of comparisons between the negative control (NC) and remofuscin-treated groups was calculated by using Student’s t-test. Significance was defined as a p-value less than 0.05 in all experiments. If the data were not normally distributed, the Mann-Whitney II test was used (Komura et al., 2013).
References
Aarnio, V., 2014. Functions of AHR-1 and CYP-35A subfamily genes in Caenorhabditis elegans. University of Eastern Finland, Kuopio https://erepo.uef.fi/bitstream/handle/123456789/14002/urn_isbn_978-952-61-1508- 5. pdf?sequence= 1 &isAllowed=y .
Bishop, N.A., Guarente, L., 2007. Two neurons mediate diet-restriction-induced longevity in C. elegans. Nature 447, 545-549.
Blasiak, J., 2020. Senescence in the pathogenesis of age-related macular degeneration. Cell. Mol. Life Sci. 77, 789-805.
Chamoli, M., Singh, A., Malik, Y., Mukhopadhyay, A., 2014. A novel kinase regulates dietary restriction-mediated longevity in Caenorhabditis elegans. Aging Cell 13, 641- 655.
Cheadle, C., Vawter, M.P., Freed, W.J., Becker, K.G., 2003. Analysis of microarray data using Z score transformation. J. Mol. Diagn. 5, 73-81.
Dexter, P.M., Caldwell, K.A., Caldwell, G.A., 2012. A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders. Neurotherapeutics 9, 393-404.
Folick, A., Oakley, H.D., Yu, Y., Armstrong, E.H., Kumari, M., Sanor, L., Moore, D.D., Ortlund, E.A., Zechner, R., Wang, M.C., 2015. Aging. Lysosomal signaling molecules regulate longevity in Caenorhabditis elegans. Science 347, 83-86.
Greer, E.L., Dowlatshahi, D., Banko, M.R., Villen, J., Hoang, K., Blanchard, D., Gygi, S.P., Brunet, A., 2007. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr. Biol. 17, 1646-1656.
Gruber, J., Ng, L.F., Poovathingal, S.K., Halliwell, B., 2009. Deceptively simple but simply deceptive-Caenorhabditis elegans lifespan studies: considerations for aging and antioxidant effects. FEBS Lett. 583, 3377-3387.
Hwangbo, D.-S., Lee, H.-Y., Abozaid, L.S., Min, K.-J., 2020. Mechanisms of Lifespan Regulation by Calorie Restriction and Intermittent Fasting in Model Organisms. Nutrients 12, 1194.
Julien-Schraermeyer S, llling B, Tschulakow A, Taubitz T, Guezguez J, Burnet M, Schraermeyer U., 2020. Penetration, distribution, and elimination of remofuscin/soraprazan in Stargardt mouse eyes following a single intravitreal injection using pharmacokinetics and transmission electron microscopic autoradiography: Implication for the local treatment of Stargardt's disease and dry age-related macular degeneration. Pharmacol. Res. Perspect. 8, e00683.
Julien, S., Schraermeyer, U., 2012. Lipofuscin can be eliminated from the retinal pigment epithelium of monkeys. Neurobiol. Aging 33, 2390-2397.
Kakimoto, Y., Okada, C., Kawabe, N., Sasaki, A., Tsukamoto, H., Nagao, R., Osawa, M., 2019. Myocardial lipofuscin accumulation in ageing and sudden cardiac death. Sci. Rep. 9, 3304.
Katairo GmbH, Takeda GmbH., 2021. Compounds for the treatment of lipofuscin related diseases. The European Patent Office, https://data.epo.org/publication- server/document?iDocld=6596891&iFormat=0.
Khan, M.H., Ligon, M., Hussey, L.R., Hufnal, B., Farber, R., 2nd, Munkacsy, E., Rodriguez, A., Dillow, A., Kahlig, E., Rea, S.L., 2013. TAF-4 is required for the life extension of isp-1, clk-1 and tpk-1 Mit mutants. Aging (Albany NY) 5, 741-758.
Komura, T., Ikeda, T., Yasui, C., Saeki, S., Nishikawa, Y., 2013. Mechanism underlying prolongevity induced by bifidobacteria in Caenorhabditis elegans. Biogerontology 14, 73-87.
Kurz, C.L., Tan, M.-W., 2004. Regulation of aging and innate immunity in C. elegans. Aging Cell 3, 185-193.
Lapierre, L.R., Gelino, S., Melendez, A., Hansen, M., 2011. Autophagy and lipid metabolism coordinately modulate life span in germline-less C. elegans. Curr. Biol. 21, 1507-1514.
Lindblom, T.H., Dodd, A.K., 2006. Xenobiotic detoxification in the nematode Caenorhabditis elegans. J. Exp. Zool. A Comp. Exp. Biol. 305, 720-730.
Lindblom, T.H., Pierce, G.J., Sluder, A.E., 2001. A C. elegans orphan nuclear receptor contributes to xenobiotic resistance. Curr. Biol. 11, 864-868.
Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408.
McElwee, J. J., Schuster, E., Blanc, E., Thomas, J.H., Gems, D., 2004. Shared transcriptional signature in Caenorhabditis elegans Dauer larvae and long-lived daf-2 mutants implicates detoxification system in longevity assurance. J. Biol. Chem. 279, 44533-44543.
Menez, C., Alberich, M., Courtot, E., Guegnard, F., Blanchard, A., Aguilaniu, H., Lespine, A., 2019. The transcription factor NHR-8: A new target to increase ivermectin efficacy in nematodes. PLoS Pathog. 15, e1007598.
Moreno-Garcia, A., Kun, A., Calero, O., Medina, M., Calero, M., 2018. An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration. Front. Neurosci. 12, 464.
Mutlu, A.S., Duffy, J., Wang, M.C., 2021. Lipid metabolism and lipid signals in aging and longevity. Dev. Cell 56, 1394-1407.
Nociari, M.M., Kiss, S., Rodriguez-Boulan, E., 2017. Lipofuscin Accumulation into and Clearance from Retinal Pigment Epithelium Lysosomes: Physiopathology and Emerging Therapeutics, in: Sharma, P.D. (Ed), Lysosomes - Associated Diseases and Methods to Study Their Function. InTechOpen, London, UK, pp. 1-29.
O'Rourke, E.J., Ruvkun, G., 2013. MXL-3 and HLH-30 transcriptionally link lipolysis and autophagy to nutrient availability. Nat. Cell Biol. 15, 668-676.
Onken, B., Driscoll, M., 2010. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN- 1. PLoS One 5, e8758.
Page, M.M., Robb, E.L., Salway, K.D., Stuart, J. A., 2010. Mitochondrial redox metabolism: aging, longevity and dietary effects. Meeh. Ageing Dev. 131 , 242-252.
Pathare, P.P., Lin, A., Bornfeldt, K.E., Taubert, S., Van Gilst, M.R., 2012. Coordinate regulation of lipid metabolism by novel nuclear receptor partnerships. PLoS Genet. 8, e1002645.
Pincus, Z., Slack, F.J., 2010. Developmental biomarkers of aging in Caenorhabditis elegans. Dev. Dyn. 239, 1306-1314.
Ramachandran, P.V., Savini, M., Folick, A.K., Hu, K., Masand, R., Graham, B.H., Wang, M.C., 2019. Lysosomal Signaling Promotes Longevity by Adjusting Mitochondrial Activity. Dev. Cell 48, 685-696.
Riddle, D.L., Blumenthal, T., Meyer, B.J., Priess, J.R., 1997. C. elegans II, second ed. Cold Spring Harbor Laboratory Press, New York.
Savini, M., Zhao, Q., Wang, M.C., 2019. Lysosomes: Signaling Hubs for Metabolic Sensing and Longevity. Trends Cell Biol. 29, 876-887.
Schmeisser, S., Priebe, S., Groth, M., Monajembashi, S., Hemmerich, P., Guthke, R., Platzer, M., Ristow, M., 2013. Neuronal ROS signaling rather than AMPK/sirtuin- mediated energy sensing links dietary restriction to lifespan extension. Mol. Metab. 2, 92-102.
Seah, N.E., de Magalhaes Filho, C.D., Petrashen, A.P., Henderson, H.R., Laguer, J., Gonzalez, J., Dillin, A., Hansen, M., Lapierre, L.R., 2016. Autophagy-mediated longevity is modulated by lipoprotein biogenesis. Autophagy 12, 261-272.
Settembre, C., Ballabio, A., 2014. Lysosome: regulator of lipid degradation pathways. Trends Cell Biol. 24, 743-750.
Sharom, F.J., 2011. The P-glycoprotein multidrug transporter. Essays Biochem. 50, 161-178.
Stiernagle, T., 2006. Maintenance of C. elegans (February 11 , 2006), WormBook, ed. The C. elegans Research Community, WormBook, doi/10.1895/wormbook.1.101.1, http://www.wormbook.org.
Sulston, J., Hodgkin, J., 1988. Methods, in: Wood, W.B. (Ed), The Nematode Caenorhabditis elegans. Cold Spring Harbor Laboratory, New York, pp. 587-606.
Tsang, S.H., Sharma, T., 2018. Stargardt Disease. Adv. Exp. Med. Biol. 1085, 139- 151.
Van Gilst, M.R., Hadjivassiliou, H., Jolly, A., Yamamoto, K.R., 2005. Nuclear hormone receptor N HR-49 controls fat consumption and fatty acid composition in C. elegans. PLoS Biol. 3, e53.
Vekshin, N., Frolova, M., 2018. Formation and Destruction of Thermo-Lipofuscin in Mitochondria. Biochem. Anal. Biochem. 7, 357.
Wang, M.C., O'Rourke, E.J., Ruvkun, G., 2008. Fat metabolism links germline stem cells and longevity in C. elegans. Science 322, 957-960.
Watts, J.L., Ristow, M., 2017. Lipid and Carbohydrate Metabolism in Caenorhabditis elegans. Genetics 207, 413-446.
Wu, D., Rea, S.L., Yashin, A. I., Johnson, T.E., 2006. Visualizing hidden heterogeneity in isogenic populations of C. elegans. Exp. Gerontol. 41, 261-270.
Yuan, Y., Kadiyala, C.S., Ching, T.T., Hakimi, P., Saha, S., Xu, H., Yuan, C., Mullangi, V., Wang, L., Fivenson, E., Hanson, R.W., Ewing, R., Hsu, A.L., Miyagi, M., Feng, Z., 2012. Enhanced energy metabolism contributes to the extended life span of calorie- restricted Caenorhabditis elegans. J. Biol. Chem. 287, 31414-31426.
Zhao, Y., Zhao, L., Zheng, X., Fu, T., Guo, H., Ren, F., 2013. Lactobacillus salivarius strain FDB89 induced longevity in Caenorhabditis elegans by dietary restriction. J. Microbiol. 51 , 183-188.
Claims
Claims: Remofuscin for use against aging. Remofuscin for use against lysomal dysfunction. Remofuscin for use disease with insufficient expression of lysosomal lipase genes and/or lysosomal lipid chaperone genes. Remofuscin for use against xenobiotic toxic effects by increasing the expression levels of the genes involved in xenobiotic detoxification through nuclear hormone receptors. Remofuscin for regular, preferably weekly or daily use according to one of claims 1-4. A tetrahydropiridoether for use according to one of claims 1-5. Use of Remofuscin for life extension or to increase xenobiotic detoxification.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22171490 | 2022-05-03 | ||
EP22171490.0 | 2022-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023213902A1 true WO2023213902A1 (en) | 2023-11-09 |
Family
ID=81940478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/061710 WO2023213902A1 (en) | 2022-05-03 | 2023-05-03 | Remofuscin (soraprazan) for use against lysosomal dysfunction and aging |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023213902A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015121441A1 (en) * | 2014-02-13 | 2015-08-20 | Katairo Gmbh | Methods for the determination of compounds or compositions for the treatment of lipofuscin related diseases and compounds or compositions |
WO2023034553A1 (en) * | 2021-09-02 | 2023-03-09 | Jcr Pharmaceuticals Co., Ltd. | Therapeutic compound for neuronal ceroid lipofuscinosis |
-
2023
- 2023-05-03 WO PCT/EP2023/061710 patent/WO2023213902A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015121441A1 (en) * | 2014-02-13 | 2015-08-20 | Katairo Gmbh | Methods for the determination of compounds or compositions for the treatment of lipofuscin related diseases and compounds or compositions |
EP3855181A1 (en) | 2014-02-13 | 2021-07-28 | Katairo GmbH | Compounds for the treatment of lipofuscin related diseases |
WO2023034553A1 (en) * | 2021-09-02 | 2023-03-09 | Jcr Pharmaceuticals Co., Ltd. | Therapeutic compound for neuronal ceroid lipofuscinosis |
Non-Patent Citations (51)
Title |
---|
BISHOP, N.A.GUARENTE, L.: "Two neurons mediate diet-restriction-induced longevity in C. elegans", NATURE, vol. 447, 2007, pages 545 - 549 |
BLASIAK, J.: "Senescence in the pathogenesis of age-related macular degeneration", CELL. MOL. LIFE SCI., vol. 77, 2020, pages 789 - 805, XP037053643, DOI: 10.1007/s00018-019-03420-x |
CHAMOLI, M.SINGH, A.MALIK, Y.MUKHOPADHYAY, A.: "A novel kinase regulates dietary restriction-mediated longevity in Caenorhabditis elegans", AGING CELL, vol. 13, 2014, pages 641 - 655 |
CHEADLE, C.VAWTER, M.P.FREED, W.J.BECKER, K.G.: "Analysis of microarray data using Z score transformation", J. MOL. DIAGN., vol. 5, 2003, pages 73 - 81, XP055154712, DOI: 10.1016/S1525-1578(10)60455-2 |
DEXTER, P.M.CALDWELL, K.A.CALDWELL, G.A.: "A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders", NEUROTHERAPEUTICS, vol. 9, 2012, pages 393 - 404 |
FANG YUAN ET AL: "Removal of RPE lipofuscin results in rescue from retinal degeneration in a mouse model of advanced Stargardt disease: Role of reactive oxygen species", FREE RADICAL BIOLOGY & MEDICINE, ELSEVIER INC, US, vol. 182, 25 February 2022 (2022-02-25), pages 132 - 149, XP087000600, ISSN: 0891-5849, [retrieved on 20220225], DOI: 10.1016/J.FREERADBIOMED.2022.02.025 * |
FOLICK, A.OAKLEY, H.D.YU, Y.ARMSTRONG, E.H.KUMARI, M.SANOR, L.MOORE, D.D.ORTLUND, E.A.ZECHNER, R.WANG, M.C.: "Aging. Lysosomal signaling molecules regulate longevity in Caenorhabditis elegans.", SCIENCE, vol. 347, 2015, pages 83 - 86 |
GREER, E.L.DOWLATSHAHI, D.BANKO, M.R.VILLEN, J.HOANG, K.BLANCHARD, D.GYGI, S.P.BRUNET, A.: "An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans.", CURR. BIOL., vol. 17, 2007, pages 1646 - 1656, XP022286033, DOI: 10.1016/j.cub.2007.08.047 |
GRUBER, J.NG, L.F.POOVATHINGAL, S.K.HALLIWELL, B.: "Deceptively simple but simply deceptive-Caenorhabditis elegans lifespan studies: considerations for aging and antioxidant effects", FEBS LETT, vol. 583, 2009, pages 3377 - 3387, XP026719689, DOI: 10.1016/j.febslet.2009.09.051 |
HWANGBO, D.-S.LEE, H.-Y.ABOZAID, L.S.MIN, K.-J.: "Mechanisms of Lifespan Regulation by Calorie Restriction and Intermittent Fasting in Model Organisms", NUTRIENTS, vol. 12, 2020, pages 1194 |
JULIEN, S.SCHRAERMEYER, U.: "Lipofuscin can be eliminated from the retinal pigment epithelium of monkeys", NEUROBIOL. AGING, vol. 33, 2012, pages 2390 - 2397, XP055157624, DOI: 10.1016/j.neurobiolaging.2011.12.009 |
JULIEN-SCHRAERMEYER S. ET AL: "Penetration, distribution, and elimination of remofuscin/ soraprazan in Stargardt mouse eyes following a single intravitreal injection using pharmacokinetics and transmission electron microscopic autoradiography: Implication for the local treatment of Stargardt's disease and dry age-related macular", EUROPE PMC PHARMACOLOGY RESEARCH & PERSPECTIVES, 1 December 2020 (2020-12-01), pages 1 - 10, XP093063290, Retrieved from the Internet <URL:https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7649431&blobtype=pdf> [retrieved on 20230712] * |
JULIEN-SCHRAERMEYER SILLING BTSCHULAKOW ATAUBITZ TGUEZGUEZ JBURNET MSCHRAERMEYER U.: "Implication for the local treatment of Stargardt's disease and dry age-related macular degeneration", PHARMACOL. RES. PERSPECT., vol. 8, 2020, pages e00683 |
KAKIMOTO, Y.OKADA, C.KAWABE, N.SASAKI, A.TSUKAMOTO, H.NAGAO, R.OSAWA, M.: "Myocardial lipofuscin accumulation in ageing and sudden cardiac death", SCI. REP, vol. 9, 2019, pages 3304 |
KHAN, M.H.LIGON, M.HUSSEY, L.R.HUFNAL, B.FARBER, R.MUNKACSY, E.RODRIGUEZ, A.DILLOW, A.KAHLIG, E.REA, S.L.: "TAF-4 is required for the life extension of isp-1, clk-1 and tpk-1 Mit mutants", AGING (ALBANY NY, vol. 5, 2013, pages 741 - 758 |
KOMURA, T.IKEDA, T.YASUI, C.SAEKI, S.NISHIKAWA, Y.: "Mechanism underlying prolongevity induced by bifidobacteria in Caenorhabditis elegans", BIOGERONTOLOGY, vol. 14, 2013, pages 73 - 87 |
KURZ, C.L.TAN, M.-W.: "Regulation of aging and innate immunity in C. elegans", AGING CELL, vol. 3, 2004, pages 185 - 193 |
LAPIERRE, L.R.GELINO, S.MELENDEZ, A.HANSEN, M.: "Autophagy and lipid metabolism coordinately modulate life span in germline-less C. elegans", CURR. BIOL., vol. 21, 2011, pages 1507 - 1514, XP028300120, DOI: 10.1016/j.cub.2011.07.042 |
LINDBLOM, T.H.DODD, A.K.: "Xenobiotic detoxification in the nematode Caenorhabditis elegans", J. EXP. ZOOL. A COMP. EXP. BIOL., vol. 305, 2006, pages 720 - 730 |
LINDBLOM, T.H.PIERCE, G.J.SLUDER, A.E.: "A C. elegans orphan nuclear receptor contributes to xenobiotic resistance", CURR. BIOL., vol. 11, 2001, pages 864 - 868 |
LIVAK, K.J.SCHMITTGEN, T.D.: "Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method", METHODS, vol. 25, 2001, pages 402 - 408 |
MCELWEE, J.J.SCHUSTER, E.BLANC, E.THOMAS, J.H.GEMS, D.: "Shared transcriptional signature in Caenorhabditis elegans Dauer larvae and long-lived daf-2 mutants implicates detoxification system in longevity assurance", J. BIOL. CHEM., vol. 279, 2004, pages 44533 - 44543 |
MEENAKSHI ET AL., AUTOPHAGY, vol. 14, no. 7, 2018, pages 1239 - 1255 |
MENEZ, C.ALBERICH, M.COURTOT, E.GUEGNARD, F.BLANCHARD, A.AGUILANIU, H.LESPINE, A.: "The transcription factor NHR-8: A new target to increase ivermectin efficacy in nematodes", PLOS PATHOG, vol. 15, 2019, pages e1007598 |
MORENO-GARCIA, A.KUN, ACALERO, O.MEDINA, M.CALERO, M.: "An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration.", FRONT. NEUROSCI., vol. 12, 2018, pages 464 |
MUTLU, A.S.DUFFY, J.WANG, M.C.: "Lipid metabolism and lipid signals in aging and longevity", DEV. CELL, vol. 56, 2021, pages 1394 - 1407, XP086574176, DOI: 10.1016/j.devcel.2021.03.034 |
NOCIARI, M.M.KISS, S.RODRIGUEZ-BOULAN, E.: "Lysosomes - Associated Diseases and Methods to Study Their Function", 2017, INTECHOPEN, LONDON, UK, article "Lipofuscin Accumulation into and Clearance from Retinal Pigment Epithelium Lysosomes: Physiopathology and Emerging Therapeutics", pages: 1 - 29 |
OH MIAE ET AL: "Remofuscin induces xenobiotic detoxification via a lysosome-to-nucleus signaling pathway to extend the Caenorhabditis elegans lifespan", SCIENTIFIC REPORTS, vol. 12, no. 1, 3 May 2022 (2022-05-03), XP093063280, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-022-11325-2> DOI: 10.1038/s41598-022-11325-2 * |
ONKEN, B.DRISCOLL, M.: "Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1", PLOS ONE, vol. 5, 2010, pages e8758 |
O'ROURKE, E.J.RUVKUN, G.: "MXL-3 and HLH-30 transcriptionally link lipolysis and autophagy to nutrient availability", NAT. CELL BIOL., vol. 15, 2013, pages 668 - 676 |
PAGE, M.M.ROBB, E.L.SALWAY, K.D.STUART, J.A.: "Mitochondrial redox metabolism: aging, longevity and dietary effects", MECH. AGEING DEV., vol. 131, 2010, pages 242 - 252, XP027035384 |
PATHARE, P.P.LIN, A.BORNFELDT, K.E.TAUBERT, S.VAN GILST, M.R.: "Coordinate regulation of lipid metabolism by novel nuclear receptor partnerships", PLOS GENET, vol. 8, 2012, pages e1002645 |
PINCUS, Z.SLACK, F.J.: "Developmental biomarkers of aging in Caenorhabditis elegans", DEV. DYN., vol. 239, 2010, pages 1306 - 1314, XP071970494, DOI: 10.1002/dvdy.22224 |
RAMACHANDRAN, P.V.SAVINI, M.FOLICK, A.K.HU, K.MASAND, R.GRAHAM, B.H.WANG, M.C.: "Lysosomal Signaling Promotes Longevity by Adjusting Mitochondrial Activity", DEV. CELL, vol. 48, 2019, pages 685 - 696 |
RATHOR LAXMI ET AL: "Folic acid supplementation at lower doses increases oxidative stress resistance and longevity inCaenorhabditis elegans", AGE, AMERICAN AGING ASSOCIATION, CHESTER, PA, US, vol. 37, no. 6, 6 November 2015 (2015-11-06), pages 1 - 15, XP035710175, ISSN: 0161-9152, [retrieved on 20151106], DOI: 10.1007/S11357-015-9850-5 * |
RIDDLE, D.L.BLUMENTHAL, T.MEYER, B.J.PRIESS, J.R.: "C. elegans II", 1997, COLD SPRING HARBOR LABORATORY PRESS |
SAVINI, M.ZHAO, Q.WANG, M.C.: "Lysosomes: Signaling Hubs for Metabolic Sensing and Longevity", TRENDS CELL BIOL, vol. 29, 2019, pages 876 - 887, XP085883872, DOI: 10.1016/j.tcb.2019.08.008 |
SCHMEISSER, S.PRIEBE, S.GROTH, M.MONAJEMBASHI, S.HEMMERICH, P.GUTHKE, R.PLATZER, M.RISTOW, M.: "Neuronal ROS signaling rather than AMPK/sirtuin-mediated energy sensing links dietary restriction to lifespan extension", MOL. METAB., vol. 2, 2013, pages 92 - 102 |
SEAH, N.E.DE MAGALHAES FILHO, C.D.PETRASHEN, A.P.HENDERSON, H.R.LAGUER, J.GONZALEZ, J.DILLIN, A.HANSEN, M.LAPIERRE, L.R.: "Autophagy-mediated longevity is modulated by lipoprotein biogenesis", AUTOPHAGY, vol. 12, 2016, pages 261 - 272 |
SETTEMBRE, C.BALLABIO, A.: "Lysosome: regulator of lipid degradation pathways", TRENDS CELL BIOL., vol. 24, 2014, pages 743 - 750 |
SHAROM, F.J.: "The P-glycoprotein multidrug transporte", ESSAYS BIOCHEM., vol. 50, 2011, pages 161 - 178 |
STIERNAGLE, T.: "The C. elegans Research Community", 11 February 2006, WORMBOOK, article "Maintenance of C. elegans" |
SULSTON, J.HODGKIN, J.: "The Nematode Caenorhabditis elegans", 1988, COLD SPRING HARBOR LABORATORY, article "Methods, in: Wood", pages: 587 - 606 |
TSANG, S.H.SHARMA, T.: "Stargardt Disease.", ADV. EXP. MED. BIOL., vol. 1085, 2018, pages 139 - 151 |
VAN GILST, M.R.HADJIVASSILIOU, H.JOLLY, A.YAMAMOTO, K.R: "Nuclear hormone receptor NHR-49 controls fat consumption and fatty acid composition in C. elegans", PLOS BIOL., vol. 3, 2005, pages e53 |
VEKSHIN, N.FROLOVA, M.: "Formation and Destruction of Thermo-Lipofuscin in Mitochondria. Biochem", ANAL. BIOCHEM., vol. 7, 2018, pages 357 |
WANG, M.C.O'ROURKE, E.J.RUVKUN, G.: "Fat metabolism links germline stem cells and longevity in C. elegans", SCIENCE, vol. 322, 2008, pages 957 - 960 |
WATTS, J.L.RISTOW, M.: "Lipid and Carbohydrate Metabolism in Caenorhabditis elegans", GENETICS, vol. 207, 2017, pages 413 - 446, XP055613971, DOI: 10.1534/genetics.117.300106 |
WU, D.REA, S.L.YASHIN, A.I.JOHNSON, T.E.: "Visualizing hidden heterogeneity in isogenic populations of C. elegans", EXP. GERONTOL., vol. 41, 2006, pages 261 - 270, XP025083249, DOI: 10.1016/j.exger.2006.01.003 |
YUAN, Y.KADIYALA, C.S.CHING, T.T.HAKIMI, P.SAHA, S.XU, H.YUAN, C.MULLANGI, V.WANG, L.FIVENSON, E.: "Enhanced energy metabolism contributes to the extended life span of calorie-restricted Caenorhabditis elegans.", J. BIOL. CHEM., vol. 287, 2012, pages 31414 - 31426 |
ZHAO, Y.ZHAO, L.ZHENG, X.FU, T.GUO, H.REN, F.: "Lactobacillus salivarius strain FDB89 induced longevity in Caenorhabditis elegans by dietary restriction.", J. MICROBIOL., vol. 51, 2013, pages 183 - 188 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shao et al. | Response of intestinal signaling communication between the nucleus and peroxisome to nanopolystyrene at a predicted environmental concentration | |
Garcia et al. | Neuronal signaling modulates protein homeostasis in Caenorhabditis elegans post-synaptic muscle cells | |
Patel et al. | Friedreich Ataxia: From GAA triplet–repeat expansion to frataxin deficiency | |
Chow et al. | Sarcopenia in the Caenorhabditis elegans pharynx correlates with muscle contraction rate over lifespan | |
Wu et al. | MPA-capped CdTe quantum dots exposure causes neurotoxic effects in nematode Caenorhabditis elegans by affecting the transporters and receptors of glutamate, serotonin and dopamine at the genetic level, or by increasing ROS, or both | |
Dancy et al. | Effects of the mitochondrial respiratory chain on longevity in C. elegans | |
Valenci et al. | Parkin modulates heteroplasmy of truncated mtDNA in Caenorhabditis elegans | |
Shao et al. | Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease | |
Bland et al. | AMPK supports growth in Drosophila by regulating muscle activity and nutrient uptake in the gut | |
Ray et al. | RTCB-1 mediates neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway | |
Rooney et al. | Effects of 5′-fluoro-2-deoxyuridine on mitochondrial biology in Caenorhabditis elegans | |
Strokin et al. | Severe disturbance in the Ca2+ signaling in astrocytes from mouse models of human infantile neuroaxonal dystrophy with mutated Pla2g6 | |
Yamada et al. | Sumoylated MEF2A coordinately eliminates orphan presynaptic sites and promotes maturation of presynaptic boutons | |
Turski et al. | Drosophila Ctr1A functions as a copper transporter essential for development | |
Kim et al. | Transcriptional regulation and life-span modulation of cytosolic aconitase and ferritin genes in C. elegans | |
Zhang et al. | The novel dipeptide Tyr-Ala (TA) significantly enhances the lifespan and healthspan of Caenorhabditis elegans | |
Mendler et al. | daf-16/FOXO and glod-4/glyoxalase-1 are required for the life-prolonging effect of human insulin under high glucose conditions in Caenorhabditis elegans | |
Hartman et al. | MANF deletion abrogates early larval Caenorhabditis elegans stress response to tunicamycin and Pseudomonas aeruginosa | |
Guan et al. | A deuterohemin peptide extends lifespan and increases stress resistance in Caenorhabditis elegans | |
Ito et al. | Metolazone upregulates mitochondrial chaperones and extends lifespan in Caenorhabditis elegans | |
Oh et al. | Remofuscin induces xenobiotic detoxification via a lysosome-to-nucleus signaling pathway to extend the Caenorhabditis elegans lifespan | |
Dong et al. | HR38, an ortholog of NR4A family nuclear receptors, mediates 20-hydroxyecdysone regulation of carbohydrate metabolism during mosquito reproduction | |
TR201807186T4 (en) | Sno rna, combinations and uses. | |
WO2023213902A1 (en) | Remofuscin (soraprazan) for use against lysosomal dysfunction and aging | |
CA2392963A1 (en) | Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23724278 Country of ref document: EP Kind code of ref document: A1 |